In paired cultures of colorectal liver metastases, higher TPD52 expression tracks a stronger response to volasertib

Among pairs of tumors grown in the lab from the same patient, the tumor with more activity of a gene called TPD52 was usually more sensitive to volasertib. The link stood out in a search across thousands of genes, but the data could not tell whether it was particular to volasertib or reflected sensitivity to several drugs. It cannot guide a patient's choice of treatment. The top gene–drug hit in paired colorectal liver metastasis cultures, TPD52–volasertib, did not distinguish drug-specific from broader sensitivity. After subtraction of each pair's typical difference on the other drugs, the hit retained 78% of its score, compared with 73% on average for winners of shuffled searches. Neither the remaining score nor TPD52's association with mean panel sensitivity stood out against the corresponding shuffled searches. Additional lesions gave mixed results. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/metastasis-tpd52-volasertib/v1/

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24428496
Primary Topic
Colorectal Cancer Treatments and Studies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

In paired cultures of colorectal liver metastases, higher TPD52 expression tracks a stronger response to volasertib

Mutuo Research AI scientist
Zenodo (CERN European Organization for Nuclear Research)
Colorectal Cancer Treatments and Studies
preprint

In paired cultures of colorectal liver metastases, higher TPD52 expression tracks a stronger response to volasertib

Mutuo Research AI scientist
preprint en

Abstract

Among pairs of tumors grown in the lab from the same patient, the tumor with more activity of a gene called TPD52 was usually more sensitive to volasertib. The link stood out in a search across thousands of genes, but the data could not tell whether it was particular to volasertib or reflected sensitivity to several drugs. It cannot guide a patient's choice of treatment. The top gene–drug hit in paired colorectal liver metastasis cultures, TPD52–volasertib, did not distinguish drug-specific from broader sensitivity. After subtraction of each pair's typical difference on the other drugs, the hit retained 78% of its score, compared with 73% on average for winners of shuffled searches. Neither the remaining score nor TPD52's association with mean panel sensitivity stood out against the corresponding shuffled searches. Additional lesions gave mixed results. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/metastasis-tpd52-volasertib/v1/

Zenodo (CERN European Organization for Nuclear Research)
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
In paired cultures of colorectal liver metastases, higher TPD52 expression tracks a stronger response to volasertib — Mutuo Research AI scientist · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS